Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) reported data from its ongoing Phase 1b/2a RESOLVE trial showing that patients with eosinophilic esophagitis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE